JO

Jco Oncology Practice

JCO Oncology Practice is an oncology journal published by ASCO that features original reports, reviews, policy and practice content, special articles, and other practice-focused cancer care research.

Looking to publish in Jco Oncology Practice? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Try Livewrite Now
Subject Oncology
Impact Factor 4.6
Quartile Q1
Open Access Type Hybrid
ISSN 2688-1527
eISSN 2688-1535
Invitation Only No

Submission Instructions

Jco Oncology Practice accepts the following article types. Click on an article type to view submission instructions.

Original Reports

Cover Letter A cover letter is required for new submissions.
Abstract An abstract is required for new submissions. Abstract must be limited to 275 words.
Manuscript Body text must be limited to 3,000 words excluding the abstract, references, figures, and tables.
References References requirements are not specified.
Figures & Tables A maximum of 6 total figures and tables is allowed, excluding any required CONSORT diagram and not including figure pieces. Table pieces are not allowed, and any additional figures or tables must be labeled 'online only' in the legends.
Reformat to Jco Oncology Practice using Livewrite Premium

Recent Publications

Health Equity for Oncology Patients in Rural America: Insurmountable Challenges or Opportunity to Make a Real Difference

Loretta J. Nastoupil, Julie MacCluskey, Emily Unterreiner, Cynthia Cathcart

10.1200/op-25-00744
View Publication

Opinion on Career Advice: Physician-Owned, Academic or Community Hospital Practice?

Barbara L. McAneny

10.1200/op-25-01332
View Publication

Commercial Health Plans and the Business of Oncology: Evolution, Cost Pressures, and Policy Responses

Lucy Langer, Michael Kolodziej

10.1200/op-25-01339
View Publication

Multidisciplinary Management of Esophageal Cancer

Anas M. Barabrah, Cindy M. Pabon, William Jin, Wayne Hofstetter, Gregory K. Mitchell, Nathaniel Deboever, Jenny Li, Mariela A. Blum Murphy

10.1200/op-26-00198
View Publication

Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study

Ignacio A. Casarini, Dariusz M. Kowalski, Christian Caglevic, Burçak Karaca Yayla, Ahmet Taner Sumbul, Patricio Yañez Weber, Alvaro N. Yanzi Castilla, Olivier Bylicki, Toshio Takagi, Kelly McQuarrie, Sanatan Saraf, Ashwini Arunachalam, Niyati Bhagwati, Graham Cohen

10.1200/op-25-01248
View Publication

Frequently asked questions

How long does it take to publish?

Average first decision turnaround time is 23 days.

Reformat to Jco Oncology Practice using Livewrite Premium

Research Topics

Economic and Financial Impacts of Cancer Cancer survivorship and care Palliative Care and End-of-Life Issues Health Systems, Economic Evaluations, Quality of Life Global Cancer Incidence and Screening Advances in Oncology and Radiotherapy Childhood Cancer Survivors' Quality of Life Lung Cancer Treatments and Mutations Ethics in Clinical Research BRCA gene mutations in cancer Cancer Genomics and Diagnostics Medication Adherence and Compliance Neutropenia and Cancer Infections COVID-19 and healthcare impacts Cancer Immunotherapy and Biomarkers Telemedicine and Telehealth Implementation Lung Cancer Diagnosis and Treatment Cancer Treatment and Pharmacology Family Support in Illness Patient-Provider Communication in Healthcare Frailty in Older Adults Colorectal Cancer Treatments and Studies Lung Cancer Research Studies Breast Cancer Treatment Studies Healthcare Policy and Management